Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Personalising care in oesophageal cancer care with liquid biopsy

Summary

The advent of ctDNA has the potential to be a game changer in some cancers, but limited data is available in oesophago-gastric cancers (OGC). The prognostic value of ctDNA and the potential for false positive results due to clonal haematopoiesis of indeterminate potential (CHIP) was recently reported in operable OGC.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: ctDNA in resected oesophago-gastric cancer: study schematic.

References

  1. 1.

    Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 545, 446–451 (2017).

    CAS  Article  Google Scholar 

  2. 2.

    Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).

    Article  Google Scholar 

  3. 3.

    Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).

    Article  Google Scholar 

  4. 4.

    Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S., Moore, K. L., Joshi, S. S. et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin. Cancer Res. 25, 7098–7112 (2019).

    CAS  Article  Google Scholar 

  5. 5.

    Leal, A., van Grieken, N. C., Palsgrove, D. N., Phallen, J., Medina, J. E., Hruban, C. et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat. Commun. 11, 1–1 (2020).

    Article  Google Scholar 

  6. 6.

    Christensen, E., Birkenkamp-Demtröder, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clini. Oncol. 37, 1547–1557 (2019).

    CAS  Article  Google Scholar 

  7. 7.

    Ococks E., Frankell A. M., Soler N. M., Grehan N., Northrop A., Coles H. et al. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann. Oncol. 32, 522–532 (2021).

  8. 8.

    Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 25, 1928–1937 (2019).

    CAS  Article  Google Scholar 

  9. 9.

    Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S. et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat. Genet. 51, 506–516 (2019).

    CAS  Article  Google Scholar 

  10. 10.

    Wasserman, I., Lee, L. H., Ogino, S., Marco, M. R., Wu, C., Chen, X. et al. SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance. Clin. Cancer Res. 25, 1948–1956 (2019).

    CAS  Article  Google Scholar 

  11. 11.

    CRUK. Cancer Statistics (2021).

  12. 12.

    Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).

    Article  Google Scholar 

  13. 13.

    Smyth, E. C., Fassan, M., Cunningham, D., Allum, W. H., Okines, A. F., Lampis, A. et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J. Clin. Oncol. 34, 2721 (2016).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We acknowledge the patients who kindly agreed to take part on the Ococks et al. study.

Author information

Affiliations

Authors

Contributions

B.de.P. and E.S. contributed equally on the draft conception, writing and review.

Corresponding author

Correspondence to Elizabeth C Smyth.

Ethics declarations

Ethics approval and consent to participate

This manuscript is based on published data, therefore ethical approval and consent is not applicable.

Data availability

The data mentioned on this manuscript is fully available online. Any further information not provided should be discussed with the corresponding authors of each cited paper.

Competing interests

Bruno de Paula declares personal consultancy fees and/or travel in the past 5 years from: Roche and Pfizer Elizabeth Smyth declares personal consultancy fees and/or travel in the past 5 years from: Aptitude Health, Astra Zeneca, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Roche, Sai-Med, Servier, Zymeworks.

Funding information

There was no funding for this manuscript.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

De Paula, B., C Smyth, E. Personalising care in oesophageal cancer care with liquid biopsy. Br J Cancer (2021). https://doi.org/10.1038/s41416-021-01370-5

Download citation

Search

Quick links